Safety and Effectiveness of Peramivir in Korean Adult Influenza Patients: Prospective Observational Study Based on Post-Marketing Surveillance Data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Ryu, Seong Yeol | - |
dc.contributor.author | Lee, Jacob | - |
dc.contributor.author | Hong, Sang-Bum | - |
dc.contributor.author | Eom, Joong Sik | - |
dc.contributor.author | Shin, Jonghwan | - |
dc.contributor.author | Park, Ki Ho | - |
dc.contributor.author | Ohk, Taekgeun | - |
dc.contributor.author | Chung, Jin-Won | - |
dc.contributor.author | Chung, Doo Ryeon | - |
dc.contributor.author | Kim, Dong Kee | - |
dc.contributor.author | Lee, Sang-Rok | - |
dc.contributor.author | Kim, Pill Young | - |
dc.contributor.author | Kim, Shin-Woo | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.available | 2020-02-27T09:42:25Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-08-06 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3462 | - |
dc.description.abstract | Background: The safety and clinical effectiveness data of peramivir in the real clinical field are limited. A prospective observational study was conducted based on the post-marketing surveillance data to evaluate the post-marketing safety and effectiveness of peramivir in Korean adults with seasonal influenza. Methods: Among adults aged 20 years or older who were diagnosed with influenza A or B, patients who started peramivir within 48 hours from the initial symptoms of influenza were enrolled. All adverse events (AEs) that occurred within 7 days after administration of peramivir were checked. For the evaluation of effectiveness, changes in the severity of influenza symptoms and daily living performance were examined before and 7 days after the administration of peramivir. The date on which influenza related symptoms disappeared was checked. Results: A total of 3,024 patients were enrolled for safety evaluation and 2,939 patients were for effectiveness evaluation. In the safety evaluation, 42 AEs were observed in 35 (1.16%) patients. The most common AE was fever. AEs were mostly rated as mild in severity. Serious AEs were observed in 10 patients and two of them died. However, both deaths were considered to be less relevant to peramivir. In the effectiveness evaluation, the severity of influenza symptoms decreased by 10.68 +/- 4.01 points and daily living performance was improved 5.59 +/- 2.16 points. Influenza related symptoms disappeared on average 3.02 +/- 2.39 days after peramivir administration. Conclusion: Peramivir showed a tolerable safety profile and acceptable effectiveness in Korean adult patients with seasonal influenza. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.subject | NEURAMINIDASE INHIBITOR PERAMIVIR | - |
dc.subject | EMERGENCY USE AUTHORIZATION | - |
dc.subject | 2009 H1N1 INFLUENZA | - |
dc.subject | INTRAVENOUS PERAMIVIR | - |
dc.subject | SEASONAL INFLUENZA | - |
dc.subject | ORAL OSELTAMIVIR | - |
dc.subject | VIRUS | - |
dc.title | Safety and Effectiveness of Peramivir in Korean Adult Influenza Patients: Prospective Observational Study Based on Post-Marketing Surveillance Data | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000440658700003 | - |
dc.identifier.doi | 10.3346/jkms.2018.33.e212 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.33, no.32 | - |
dc.identifier.kciid | ART002372477 | - |
dc.identifier.scopusid | 2-s2.0-85051074628 | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 33 | - |
dc.citation.number | 32 | - |
dc.contributor.affiliatedAuthor | Eom, Joong Sik | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Influenza | - |
dc.subject.keywordAuthor | Antiviral | - |
dc.subject.keywordAuthor | Peramivir | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Effectiveness | - |
dc.subject.keywordAuthor | Clinical Trial | - |
dc.subject.keywordPlus | NEURAMINIDASE INHIBITOR PERAMIVIR | - |
dc.subject.keywordPlus | EMERGENCY USE AUTHORIZATION | - |
dc.subject.keywordPlus | 2009 H1N1 INFLUENZA | - |
dc.subject.keywordPlus | INTRAVENOUS PERAMIVIR | - |
dc.subject.keywordPlus | SEASONAL INFLUENZA | - |
dc.subject.keywordPlus | ORAL OSELTAMIVIR | - |
dc.subject.keywordPlus | VIRUS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.